Exact sciences corporation stock.
Exact Sciences Corp. lowest stock price was $40.73 and its highest was $100.77 in the past 12 months. What is Exact Sciences Corp.’s market cap? ... Exact Sciences Corp. released its earnings results on Nov 01, 2023. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.471. ...
Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023 Nov. 01: CI Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023 Nov. 01: CI Exact Sciences Corp. Announces Late …13-Mar-2021 ... ... CORP ,INCY, BMY, IONIS PHARMACEUTICALS INC ,IONS, EXPERIENCE INVESTMENT CORP-A ,EXPC, ALIBABA GROUP HOLDING-SP ADR ,BABA, ACCOLADE INC ,ACCD ...Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 16.9% so far this month. During the month of September, Exact Sciences Corp’s stock price has reached a high of $85.71 and a low of $69.26. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $29.27. Year to date, Exact ...Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.
Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.
Exact Sciences to take portion of initial payment in common stock of mdxhealth; Raising previously issued FY 2022 mdxhealth revenue guidance to $27-29 million; ... a subsidiary of Exact Sciences Corporation (“Exact Sciences“), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences along with …On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...01-Aug-2023 ... MADISON, Wis., Aug. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...Get EXACT Sciences Corporation (EXAS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...Jul 19, 2023 · Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...
16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...
Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...
04-Jan-2023 ... As illustrated in our open-source model, shares of Exact Sciences could compound at an average annual rate of 25%, reaching $140 by 2027.According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 39.52%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ...Imperialism exists today, but not in the exact form practiced during the Roman Empire or the British Empire. Capitalism is a major driver of modern imperialism as corporations, such as banks and oil companies, expand globally to generate mo...Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...
27-Oct-2020 ... ... stock consideration of up to $2.15 billion. The transaction was ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719.Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... MADISON, Wis., Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $521.6 million for the second quarter ended June 30, 2022, compared to $434.8 million for the same period of 2021.
Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.
View live Exact Sciences Corporation chart to track its stock's price action. Find market predictions, EXAS financials and market news.About Exact Sciences Corp. ... Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was $4.2 million and $8.2 million for the three and nine months ended September 30, 2020.Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsExact Sciences Corp. completed the acquisition of Thrive Earlier Detection Corp. in a cash and stock deal valued at up to $2.15 billion. Under the previously disclosed terms of the deal, Thrive's shareholders were to receive $1.7 billion at closing, consisting of 65% in Exact Sciences common stock and 35% in cash. Thrive would also be eligible ...The stock price for Madison-based cancer screening and diagnostic test company Exact Sciences Corp. soared Wednesday after the company reported higher-than-expected sales in the first quarter.Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Mar 3, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 8.31% so far this month. During the month of March, Exact Sciences Corp’s stock price has reached a high of $67.82 and a low of $60.85. Over the last year, Exact Sciences Corp has hit prices as high as $76.94 and as low as $29.27. Year to date, Exact ... Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Sep 30, 2023 · Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ...
Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!
EXACT Sciences Corporation (EXAS) NASDAQ Currency in USD Disclaimer Add to Watchlist 63.77 +0.32 (+0.50%) Real-time Data 14:22:38 Fair Value Unlock Value Day's …Jul 10, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ... Find the latest historical data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqThe company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...Aug 2, 2023View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77.
Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...June 7, 2023 at 10:53 AM · 4 min read. Exact Sciences Corporation EXAS is well poised for growth in coming quarters, led by the continued strength across the Screening and Precision Oncology ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...Instagram:https://instagram. share tipsgeo group inc stocky mabs therapeuticsezgo stock The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company. flower turbine costwhat are the best investments for 401k right now Oct 20, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ... Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ... dividend income estimator View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Aug 2, 2022 · Under the terms of the asset purchase agreement, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which ...